Gene Editing Market: Growth, Size, Share, and Trends

Report Code BT 3380
Published in Nov, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

Market Growth Outlook Summary

The global gene editing market growth forecasted to transform from USD 4.66 billion in 2024 to USD 7.59 billion by 2029, driven by a CAGR of 10.2%. Market growth is attributed to factors such as advancements in gene editing technologies, the expanding range of gene editing applications, rising demand for personalized medicine, and the growing prevalence of congenital disorders. However, the market faces several challenges, including off-target effects of gene editing and issues with scalability and manufacturing, which pose significant hurdles.

Gene Editing Market – Global Forecast and Key Opportunities to 2029

North America

Growth in the North American gene editing market can be attributed the surge in development and approval of advanced therapies requiring gene editing products and services.

The expanding scope of gene editing applications, compounded by introduction of new technologies such as bridge RNA and prime editing along with rising government funding and support to gene editing research is driving the market

Expanding pipeline candidates which utilize gene editing for manufacture and increased demand for personalized medicine along with rise in global infant and congenital disorders present significant growth opportunities for this market

Off Target effects, along with high equipment and facility costs can limit the growth of this market.

Globally, North America is the largest market for gene editing and this trend is expected to continue during the forecast period.

Gene Editing Market Dynamics to 2029

DRIVER: Expanding scope of gene editing applications

Cell and gene therapies are advanced therapies used to treat a wide range of diseases such as cancer, cystic fibrosis, heart disease, and genetic disorders. Cell therapy is referred to a therapy in which viable cells are injected or implanted into patient’s body to get therapeutic effects. On the other hand, gene therapy is the medical technology used to produce therapeutic effect through manipulation of gene expressions. Thus, cell and gene therapies are widely used for the treatment of genetic and rare diseases. The adoption of cell & gene therapy has increased over the last few years, and this trend is expected to continue in the coming years due to the high and rising incidence of cancer and other rare diseases. For instance, to data released by GLOBOCAN in 2020, it was estimated that 19.3 million cases new cancer cases and 10.0 million cancer deaths occurred in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Therefore, increasing need of cell & gene therapy due to rising prevalence of chronic diseases is propelling the growth of transfection technologies market.

RESTRAINT: Off-target effects and safety concerns.

Off-target effects and safety concerns limit gene editing market expansion. Despite its precision in gene editing, CRISPR-Cas9 encounters off-target DNA cleavage effects. The single-guide RNA (sgRNA) can guide the Cas9 enzyme to splice DNA at mistargeted locations in the genome. Such effects can cause non-specific and hazardous gene modifications, reducing gene editing's therapeutic application. Many methods have been developed to decrease off-target effects, including sgRNA optimization, Cas9 nuclease modifications, and prime editors. These advancements are not failsafe, and off-target consequences remain a concern, especially in precision-driven therapeutics. The safety of gene editing extends beyond the patient to laboratory and clinical workers and close contacts. The use of viral vectors like adeno-associated viruses (AAVs) for gene delivery requires strict safety precautions to avoid genome integration or infection. Another ethical and safety issue is germline editing, which could affect future generations. These factors make the market cautious, restricting gene editing technology adoption until these hazards are known and managed.

 

OPPORTUNITY: Technological advancements in Prime editing and bridge RNA

New directions in gene editing are being opened by advancements such prime editing and bridge RNA technologies, which offer more exact and effective solutions. Combining Cas9 with reverse transcriptase and prime editing guide RNA improves accuracy by means of a modification of the CRISPR-Cas9 system, thus permitting repair of single base mutations and DNA insertions without double-stranded breaks, so minimizing off-target effects. Research by AstraZeneca in March 2022 revealed the promise of prime editing for exact DNA insertions with low deletions. Targeting rare immunodeficiency, chronic granulomatosis disease (CGD), Prime Medicine's candidate PM3Sg was approved by the FDA for Phase I/II trials.

Another approach is Bridge RNA, which minimizes collateral damage by joining target DNA with desired sequences thereby enabling large-scale DNA modifications in one stroke. The Broad Institute showed in June 2024 that bridge RNA could insert sizable DNA fragments into human cells, hence enhancing gene-editing precision. These developments improve the safety and accuracy of gene editing, hence increasing the therapeutic possibilities. New directions in gene editing are being opened by advancements such prime editing and bridge RNA technologies, which offer more exact and effective solutions. Combining Cas9 with reverse transcriptase and prime editing guide RNA improves accuracy by means of a modification of the CRISPR-Cas9 system, thus permitting repair of single base mutations and DNA insertions without double-stranded breaks, so minimizing off-target effects. Research by AstraZeneca in March 2022 revealed the promise of prime editing for exact DNA insertions with low deletions. Targeting rare immunodeficiency, chronic granulomatosis disease (CGD), Prime Medicine's candidate PM3Sg got FDA permission for Phase I/II trials.

CHALLENGES: Issues with scalability of gene editing workflows

Gene editing workflow scalability and manufacturing challenges limit market growth. Gene editing workflows like ex vivo approaches, are intricate and expensive. This complexity is aggravated by the difficulties of expanding operations from clinical and experimental use with few applications to bigger commercial uses. Demand for raw materials has caused significant shortages for manufacturing slots at CDMOs & CROs. Sponsors have encountered 18–24-month delays, slowing gene editing program progress. Some larger biopharmaceutical businesses have invested in their own production facilities to manage their supply chains, which smaller biotech firms are unable to accomplish. These start-ups rely on external vendors, which can limit their output and cost control. Scaling up production is difficult since it requires balancing therapeutic efficacy, toxicity, and immunogenicity. Despite advances in delivery technology, viral vectors such as rAAV are preferred because of their ability to transduce a large number of cells and low immunogenicity. The rising demand for rAAV vectors and their production complexity continue to challenge the gene editing market, potentially slowing the transition from clinical trials and research to widespread commercial application.

Gene Editing Market Map & Ecosystem Overview

The gene editing market ecosystem encompasses product, service, end user, and regulatory authorities. Gene Editing Product Providers create kits, reagents, software, and technologies like CRISPR and TALENs for gene editing. Gene Editing Service Providers provide unique gene editing, consulting, and technical assistance to clients who need customized solutions or lack in-house knowledge. Academic institutions, biotechnology, and pharmaceutical companies, and CROs use gene editing technologies and services for drug discovery, gene therapy development, and agricultural biotechnology. Their actions drive gene editing product and service demand. Gene editing products and services must meet safety, effectiveness, and ethical requirements set by regulators. These bodies regulate gene editing technology research and use, particularly in clinical and therapeutic settings. The gene editing market ecosystem is shaped by product, service, end user, and regulatory interactions.

 

The CRISPR segment accounted for the largest share of the product technology segment of the gene editing market in 2023.

The gene editing market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include Piggybac, Prime editing among others. The CRISPR segment held the highest share of the gene editing products market by technology driven by advancements in CRISPR technology, products cater to a range of CRISPR applications, from gene knockout to precise gene correction or insertions using tools like donor oligos and design software for CRISPR-based genome editing. However, TALEN held the second highest share of the gene editing market. The gene editing products market for CRISPR technologies is expanding, with various companies offering a variety of tools and reagents. Cas9 proteins are vital products, with variants like wild-type, enhanced specificity, nickase, and GFP-fused versions available. Merck KGaA (Germany) offers Cas9 proteins and CRISPR activation and inhibition libraries, while Integrated DNA Technologies, Inc. (US) provides guide RNAs and Alt-R HDR donor oligos for homology-directed repair (HDR) experiments. Takara Bio Inc. (Japan) supplies CRISPR kits like the Guide-it sgRNA in vitro transcription kit. Revvity, Inc. (US) offers genome-wide CRISPR screening libraries.

The pharmaceutical & biotechnology segment accounted for the largest share of the services end user segment of the gene editing market in 2023.

By services end user, the gene editing market is segmented into pharmaceutical & biotechnology companies, Academic & research institutes, and other end users which include diagnostic companies, biobanks, and small-scale CDMOs among others. Pharmaceutical & biotechnology companies held the highest share of the market as they utilize various types of services such as cell line development and engineering, gRNA synthesis & vector construction, and Library construction and screening for various applications such as drug discovery and development. However Academic and research institutes held the second highest share of the gene editing services by end user. Pharmaceutical & biotechnology companies are the key end users of the gene editing services market as these firms utilize services such as cell line development & engineering, gRNA synthesis & vector construction, and library construction and screening for drug discovery and development. For instance, in June 2024, Revvity, Inc. (US) collaborated with GenKOre (South Korea) to develop gene therapies for ocular disorders using Revvity’s AAV vectors. Revvity, Inc. also collaborated with AstraZeneca plc (UK) to use Revvity’s gene editing services for drug development in May 2023. The utilization of library construction & screening services to create in-house platform technologies for research & target identification is vital. For Instance, in February 2023, Tecan Life Sciences (UK) collaborated with Singular Genomics (US) to create libraries for the G4 Sequencing platform

The North American region accounted for the largest share of the gene editing market in 2023.

The gene editing market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest regional market for gene editing in 2023, while Europe is the second-largest market. The large share of North America can be attributed to the surge in development and approval of advanced therapies requiring gene editing products and services. However, The Asia Pacific is estimated to be the fastest-growing segment of the market characterized by a significant focus on R&D activities to broaden the scope of genomics applications, increasing adoption of genomics technologies for diagnostics, and technological developments in genomic data analysis. The gene editing market in the United States is distinguished by a collaborative environment, strong government support, major investment, and R&D initiatives. The US National Institutes of Health (NIH) has been a key driver, investing USD 814 million in gene editing projects as of September 2024, including the Somatic Cell Genome Editing (SCGE) program, which received more than USD 140 million in funding in July 2023 to accelerate genome editing from lab research to clinical applications. Furthermore, the NIH will provide USD 22 million to UC Berkeley and Ohio State University in July 2023 to explore CRISPR-based therapeutics for neurological illnesses, demonstrating the government's commitment to promoting research.

HIGHEST CAGR MARKET IN 2024
US FASTEST GROWING MARKET IN THE REGION

Gene Editing Market Recent Developments and Insights

  • In July 2024, Agilent Technologies, Inc. (US) acquired BIOVECTRA, Inc. (Canada), enhancing its biopharma solutions with BIOVECTRA’s expertise in biologics and gene editing. The acquisition expanded Agilent’s capabilities in drug development and manufacturing.
  • In June 2024, GenKOre (South Korea) and Revvity (US) collaborated to develop gene therapies for ocular disorders using GenKOre's TaRGET platform and Revvity's AAV vectors. The partnership aimed to advance in vivo gene-editing therapies for Leber Congenital Amaurosis 10 and Usher Syndrome Type 2A, potentially leading to expanded development and commercialization opportunities.
  • In May 2024, Merck KGaA (Germany), acquired Mirus Bio, Inc. (US), integrating Mirus Bio's transfection technology with Merck's bioprocessing expertise. This acquisition, completed enhanced Merck’s capabilities in viral vector manufacturing, advancing support for cell and gene therapies.
  • In March 2023, GenScript (US) announced a strategic collaboration with PersonGen-Anke Cellular Therapeutics (US) to advance cell isolation products. This partnership aimed to enhance cell therapy development and production efficiency. GenScript's CytoSinct platform was expected to support PersonGen in reducing costs and improving R&D efficiency in cell therapy.

Gene Editing Market – Leading Key Players Analysis

Want to explore hidden markets that can drive new revenue in Gene Editing Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million)
Segments covered Offerings, Products by Type, Reagents & Consumables by Technique, Products by Technology, Products by Application, Products by End User, Services by Type, Services By Application, Services by End User.
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Key Questions Addressed by the Report

The global gene editing market is projected to grow from USD 4.66 billion in 2024 to USD 7.59 billion by 2029, demonstrating a robust CAGR of 10.2%.
The major factors driving market growth include technological advancements in gene editing tools like CRISPR, TALEN, and ZFN, increased demand for personalized medicine, and government investments supporting gene editing research. Additionally, the growing burden of genetic disorders and the potential of gene-based therapies further fuel the market's expansion.
CRISPR technology holds the largest share of the gene editing market due to its high precision and efficiency in gene modification. It is widely used in various applications, including gene knockout, gene correction, and genome editing.
The cell line engineering application segment holds the largest share in the gene editing market. The demand for precise cell line development for drug discovery, genetic research, and therapeutic applications contributes to this growth.
North America leads the gene editing market due to the high concentration of research institutions, strong government support, and advancements in gene-based therapies. Europe follows as the second-largest market, with substantial investments in biotechnology and gene editing research.
Prime editing and base editing are expected to witness the highest growth in the gene editing market. These technologies offer higher precision and fewer off-target effects compared to traditional methods like CRISPR and TALEN, making them increasingly popular for genetic modifications.
Key players in the gene editing market include Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Agilent Technologies, and Revvity. These companies are adopting organic and inorganic growth strategies such as acquisitions, partnerships, and new product developments to strengthen their market positions.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Gene Editing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
16
EXECUTIVE SUMMARY
27
PREMIUM INSIGHTS
47
MARKET OVERVIEW
63
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 IMPACT OF AI/GEN AI
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - NEXT-GENERATION SEQUENCING
    - ELECTROPORATION
    - MICROINJECTION
    COMPLEMENTARY TECHNOLOGIES
    - SYNTHETIC BIOLOGY
    - DATA ANALYSIS
    - HIGH-THROUGHPUT SCREENING
    ADJACENT TECHNOLOGIES
    - SINGLE CELL ANALYSIS
    - OPTOGENETICS
    - GENE DELIVERY SYSTEMS
  • 5.10 PATENT ANALYSIS
  • 5.11 KEY CONFERENCES & EVENTS 2024-2025
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTE
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITION RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN THE BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 5.15 CASE STUDIES (TOP 3-5 PLAYERS)
  • 5.16 INVESTMENT AND FUNDING SCENARIO
  • 5.17 TRADE DATA ANALYSIS (BEST EFFORT BASIS)
GENE EDITING PRODUCTS MARKET, BY TYPE
87
  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & CONSUMABLES
    GENE EDITING KITS (INCLUDES MUTATION KITS, SCREENING KITS, GENETIC ENGINEETING KITS)
    GENE EDITING LIBRARIES
    GENE EDITING REAGENTS (INCLUDES ANTIBODIES, ENZYMES, AND CONTROLS)
  • 6.3 SOFTWARE & SYSTEMS
GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE
91
  • 7.1 INTRODUCTION
  • 7.2 KNOCK-OUT
  • 7.3 KNOCK-IN
  • 7.4 GENE SILENCING
  • 7.5 OTHER TECHNIQUES (JUMP-IN, HOMOLOGOUS RECOMBINATION, GENE OVEREXPRESSION AND OTHERS)
GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY
116
  • 8.1 INTRODUCTION
  • 8.2 CRISPR
  • 8.3 TALEN
  • 8.4 ZFN
  • 8.5 BASE EDITING
  • 8.6 ANTISENSE
  • 8.7 RNAI
  • 8.8 OTHER TECHNOLOGIES (INCLUDES PIGGYBAC, PRIME EDITING AND OTHERS)
GENE EDITING PRODUCTS MARKET, BY APPLICATION
135
  • 9.1 INTRODUCTION
  • 9.2 CELL LINE ENGINEERING
  • 9.3 GENOME EDITING/GENETIC ENGINEERING
  • 9.4 DRUG DISCOVERY AND DEVELOPMENT
  • 9.5 OTHER APPLICATIONS (INCLUDES CLINICAL DIAGNOSTICS, XENOTRANSPLANTATION AND OTHERS)
GENE EDITING PRODUCTS MARKET, BY END USERS
145
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.4 CROS & CDMOS
  • 10.5 OTHER END USERS (BIOBANKS, DIAGNOSTIC COMPANIES)
GENE EDITING SERVICES MARKET, BY TYPE
167
  • 11.1 INTRODUCTION
  • 11.2 CELL LINE DEVELOPMENT & ENGINEERING
  • 11.3 GRNA SYNTHETSIS & VECTOR CONSTRUCTION
  • 11.4 LIBRARY CONSTRUCTION & SCREENING
  • 11.5 OTHER SERVICES (IF ANY)
GENE EDITING SERVICES MARKET, BY APPLICATION
191
  • 12.1 INTRODUCTION
  • 12.2 CELL LINE ENGINEERING
  • 12.3 GENOME EDITING/GENETIC ENGINEERING
  • 12.4 DRUG DISCOVERY AND DEVELOPMENT
    BLOOD DISORDERS
    CANCER
    CNS
    OTHERS (INCLUDES OPHTHALMOLOGY, INFECTIONS, DYSTROPHIES AND OTHERS)
  • 12.5 OTHER APPLICATIONS (INCLUDES CLINICAL DIAGNOSTICS, XENOTRANSPLANTATION AND OTHERS)
GENE EDITING SERVICES MARKET, BY END USERS
201
  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.3 ACADEMIC & RESEARCH INSTITUTES
  • 13.4 OTHER END USERS (BIOBANKS, DIAGNOSTIC COMPANIES, SMALL-SCALE CDMOS, CROS)
GENE EDITING MARKET, BY REGION
223
  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 14.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    FRANCE
    UK
    ITALY
    SPAIN
    REST OF EUROPE
  • 14.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    CHINA
    INDIA
    SOUTH KOREA
    AUSTRALIA
    REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC
    - SAUDI ARABIA (KSA)
    - REST OF GCC
    REST OF MIDDLE EAST
  • 14.7 AFRICA
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
237
  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
  • 15.3 REVENUE SHARE ANALYSIS (TOP PLAYERS), 2019-2023
  • 15.4 MARKET SHARE ANALYSIS (TOP PLAYERS), 2023
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - PRODUCT FOOTPRINT
    - SERVICE FOOTPRINT
    - TECHNOLOGY FOOTPRINT
    - APPLICATION FOOTPRINT
  • 15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF KEY STARTUPS/ SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
  • 15.7 COMPETITIVE SCENARIO
    DEALS
    OTHER DEVELOPMENTS
  • 15.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
  • 15.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE GENE EDITING MARKET
COMPANY PROFILES
249
  • 16.1 KEY COMPANIES
    THERMO FISHER SCIENTIFIC
    MERCK KGAA
    GENSCRIPT
    AGILENT TECHNOLOGIES, INC.
    REVVITY, INC.
    LONZA
    TECAN LIFE SCIENCES
    SANGAMO THERAPEUTICS
    PRECISION BIOSCIENCES
    CELLECTIS S.A.
    REGENERON PHARMACEUTICALS, INC.
    AMSBIO
    CREATIVE BIOGENE
    SYNTHEGO CORPORATION
    TAKARA BIO, INC.
    BIO-TECHNE
    CARIBOU BIOSCIENCES
    BIONEER CORPORATION
    REPROCELL, INC.
    ALSTEMCELL ADVANCEMENTS
  • 16.2 OTHER PLAYERS
    NEW ENGLAND BIOLABS
    ORIGENE TECHNOLOGIES
    INSCRIPTA
    BIOCAT
    COBO SCIENTIFIC
    GENECOPOEIA
    INTEGRATED DNA TECHNOLOGIES, INC.
    HERA BIOLABS
    CELLECTA BIOSCIENCES
    APPLIED STEMCELL INC
    STEMCELL TECHNOLOGIES
APPENDIX
267
  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 17.3 AVAILABLE CUSTOMIZATIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

This study on the gene editing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the gene editing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India). Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global gene editing market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global gene editing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the gene editing market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The gene editing market, as covered within the scope of this report, includes products, technologies, and services that facilitate genetic modifications across various applications. This encompasses reagents and consumables, as well as software and systems for planning, executing, and analyzing gene editing processes. Additionally, the report covers services that utilize gene editing technologies like CRISPR, TALEN, ZFN, and other methods such as Meganucleases, PiggyBac, and Prime Editing, applied in areas like cell line engineering, genome editing, drug discovery, clinical diagnostics, and xenotransplantation. These components serve end users, including pharmaceutical and biotechnology companies involved in therapeutic development, as well as academic and research institutes focused on scientific research.

Stakeholders

  • Manufacturers and distributors of gene editing products and services
  • Pharmaceutical and biotechnology companies
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes
  • CDMOs & CROs
  • Biobanks
  • Diagnostic companies.

Report Objectives

  • To define, describe, segment, and forecast the gene editing market based on offerings, product type, product application, product technology, reagent & consumables technique, product end user, service type, service application, service end user and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
  • To strategically profile the key players in the global gene editing market and comprehensively analyze their core competencies2 and market rankings.
  • To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
  • To profile the key players in the global gene editing market and comprehensively analyze their instruments, reagents, kits, consumables, and services portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the gene editing market
  • To benchmark players within the gene editing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

Previous Versions of this Report

Genome Editing Market Growth by Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics), End user (Pharmaceutical, Biotechnology, Academia) - Global Forecast to 2026

Report Code BT 3380
Published in Jul, 2023, By MarketsandMarkets™

Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics), End user (Pharmaceutical, Biotechnology, Academia) - Global Forecast to 2026

Report Code BT 3380
Published in Nov, 2021, By MarketsandMarkets™

Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics, Drug Discovery & Development), End-User and Region - Global Forecast to 2025

Report Code BT 3380
Published in Jun, 2020, By MarketsandMarkets™

Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022

Report Code BT 3380
Published in Nov, 2017, By MarketsandMarkets™

Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Applications (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs - Global Forecast to 2021

Report Code BT 3380
Published in Oct, 2016, By MarketsandMarkets™

Genome Editing / Genome Engineering Market by Application (Cell Line Engineering, Animal & Plant Genetic Engineering), Technology (CRISPR, Antisense, TALEN, Zinc Finger Nuclease) & End User (Biotechnology & Pharmaceutical, CRO) - Global Forecast to 2019

Report Code BT 3380
Published in Apr, 2015, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Gene Editing Market

DMCA.com Protection Status